The in vitro antifungal activity of
luliconazole, a novel topical
imidazole, against pathogenic fungi implicated in
dermatomycoses was studied. A total of 91 clinical isolates, consisting of 59 Trichophyton rubrum isolates, 26 T. mentagrophytes isolates, 1 Epidermophyton floccosum isolate, and 5 Candida albicans isolates were tested by the broth microdilution method, employing
lanoconazole,
terbinafine, and
bifonazole as reference drugs. The minimum inhibitory concentrations (MICs) of
luliconazole against T. rubrum and T. mentagrophytes were in the range of 0.00012-0.004 microg/ml and 0.00024-0.002 microg/ml, respectively. The MIC90 of
luliconazole for these two species of dermatophytes was the same, at 0.001 microg/ml, and these values were 4 times, 30 times, and more than 1000 times lower than those of
lanoconazole,
terbinafine, and
bifonazole, respectively. Similarly, the 1 isolate of E. floccosum tested was inhibited by
luliconazole with an MIC of 0.001 microg/ml.
Luliconazole also proved to be very potent against C. albicans (MIC range, 0.031-0.25 microg/ml), nearly on par, in terms of efficacy, with
lanoconazole (0.063-0.25 microg/ml) and more potent than
terbinafine (2->64 microg/ml) and
bifonazole (0.5-4 microg/ml). These results showed that
luliconazole was very potent in vitro against pathogenic fungi isolated from patients with
dermatomycoses, and these findings emphasized the utility of
luliconazole for the topical management of this condition.